Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028 Report Analysis and Data Highlights:
- Research Methodology
- Global and Regional Market Analysis
- Global Bispecific Antibody Market Opportunity Assessment: > USD 20 Billion
- Market and Drug Sales Insight 2020 Till 2028
- Approved Drug In Market: 3 Drugs
- Approved Bispecific Antibody Drug Patent, Price and Sales insight 2020 Till 2028
- Future Market Assessment By Indication Till 2028
- Ongoing Clinical Trials Assessment by Status, Phase and Region
- Key Market Dynamics
- Competitor Landscape
The advancement in the field of biotechnology and increased understanding about the progression of disease has led to development of more effective therapies in the treatment of several disorders. In last few years, bispecific antibodies have entered the market which has dual binding mechanism. In contrast to conventional monoclonal antibodies which have both binding sites directed at the same target, bispecific antibodies have the ability to simultaneously bind two different targets. The introduction of bispecific antibodies has greatly reformed the global therapeutics market.
Presently, three bispecific antibodies are available in market including Blincyto, Hemlibra, and Rybrevant. Blincyto (Blinatumomab) is a bispecific CD19 directed CD3 T-cell engager indicated for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia. The drug was developed by Amgen and was approved in 2014. Later in 2017, Genentech developed Hemlimbra which is a bispecific factor IXA and factor X-directed antibody indicated to prevent or reduce the frequency of bleeding episodes in patients with Hemophilia A. In 2021, Rybrevant (Amivantamab) developed by Janssen Pharmaceuticals was also granted approval. It is first fully-human bispecific antibody directed against EGFR and MET receptors and indicated for the management of non-small cell lung cancer.
The advent of bispecific antibodies have shown to confer several advantages over monoclonal antibodies in terms of efficacy and binding affinity. Owing to its small molecular weight, bispecific antibodies are comparatively cheap to manufacture as well as also has the ability to cross the blood brain barrier. In addition, these are associated with lesser side effects in comparison to monoclonal antibodies and other conventional cancer therapies. Researchers have demonstrated the role of bispecific antibodies in plethora of diseases including cancer, hemophilia, auto-immune disorders, influenza, and others. The widespread use of these antibodies will drive the growth of market during the forecast period.
The bispecific antibodies have generated spark in last decade with several pharmaceutical companies developed their proprietary bispecific development platforms including CrossMab (Roche), Duobody (Genmab), DVD-IgG (Abbvie), DART (Macrogenics), XmAb (Xencor), and several others. The pipeline for the novel bispecific antibody is highly crowded and consists of about 100 candidates. Our report findings suggests that around 4 to 5 bispecific antibodies are expected to enter the market by 2028, which will further boost the growth of market during the forecast period.
Despite their several advantages, the increased complexity associated with dual targeting can also possess challenge during the drug designing and development process. However, the continuous technological advancements have considerably improved the production of therapeutic antibodies. In addition, advancement in protein engineering technologies will also boost the development of bispecific antibodies and their derivatives. The global bispecific antibody market is poised to grow for next few years and is estimated to surpass USD 40 Billion by 2028. Several factors including increase in prevalence of cancer and other disorders, robust sales of approved drugs, and increasing awareness among the population are attributed for market growth.
Our report further suggests that US followed by Europe will dominate the global market. In Europe and US, growing incidence of chronic diseases such as lung cancer, cervical cancer, breast cancer, and prostate cancer is increasing, with the regions accounting for the highest incidence rate for these diseases worldwide. Moreover, with these regions being home to major players, these are the largest bispecific antibodies market. In addition, rising initiatives by government and development of favorable reimbursement policies will also fuel the growth of market. Furthermore, improvement in healthcare access and awareness in developing regions such as Asia Pacific, Latin America, and Middle East are again expected to propel demand for bispecific antibody due to fuel growth of the bispecific antibodies market in the near future.